The glucagon component is also what explains retatrutide's most distinctive side effect: dysesthesia (abnormal skin sensations) in 12.520.9% of patients depending on trial, which is not seen with semaglutide or any other approved weight loss medication
4,5 Clinical outcomes Across phase II data for the once-daily, non-peptide GLP-1R agonist orforglipron in obese adults without diabetes, mean weight loss of 9.414.7% 6 was reported by week 36, depending on the dose, as compared to 2.3% with placebo
[3] Individual Factors That Matter Not everyone taking GLP-1 medications will develop iron deficiency, but certain factors may increase your risk: Medical History: People with low iron stores, history of anemia, or conditions affecting iron absorption (like celiac disease or inflammatory bowel disease) may be more vulnerable
The trial demonstrated that oral semaglutide was non-inferior to placebo in this aspect
Compounded Semaglutide is an anti-diabetic and anti-obesity medication intended to address the challenges associated with the management of type 2 diabetes and obesity
The effects of glutathione treatments start fading over time
